References
Mean age (years)
Number of patients
Sex
Treatment regimen
Duration of follow-up (months)
Stage of disease
Mitotane levels (mg L-1)
Overall response rate
Overall survival (months)
Disease-free survival
Progression-free survival
[20]
50
50
Male (n=24) Female (n=26)
M+A or A
16.5
IV
Not recorded
M+A=48% a A=48% a
10.6
NA
2.6 months
[7]
47
28
Male (n=10) Female (n=18)
M+E+D+C
NA
II (n=2) III (n=6) IV (n=20)
Not recorded
53.5%b
NA
NA
NA
[21]
50
72
Male (n=24) Female (n=48)
M+E+D+C
120
I (n=1) II (n=24) III (n=30) IV (n=17)
Not recorded
48.6% b
Male=23.6 Female=38.6 ≤2 years=26.4 months ≥2 years=51.7 months
NA
[18]
50
304
Male (n=121) Female (n=183) M+E+D+CM+Sz c M+SzM+E+D+C c
78
III (n=1) IV (n=303)
14-20
First-line therapy: M+E+D+C=23.2% a M+Sz=9.2% a First-line therapy: M+E+D+C=14.8 M+Sz=12
NA
First-line therapy: M+E+D+C=5 months M+Sz=2.1 months Second-line therapy: M+E+D+CM+Sz=5.6 months M+SzM+E+D+C=2.2 months
[22]
54
37
Male (n=19) Female (n=18)
M+C
NA
IV
Not recorded
30% d
11.8
NA
NA
[23]
46.5
45
Male (n=23) Female (n=22) E+C E+CM (n=16) e
NA
III (n=2) IV (n=43)
Not recorded
13% f
10
NA
NA
[19]
44.4
36
Male (n=11) Female (n=25)
M+E+D+V
34.8
IV
10–15
22% g
13.5
NA
NA